1. Meier DA, Brill DR, Becker DV, Clarke SE, Silberstein EB, Royal HD, et al. Procedure guideline for therapy of thyroid disease with (131)iodine. J Nucl Med. 2002. 43(6):856–861.
2. Luster M, Clarke SE, Dietlein M, Lassmann M, Lind P, Oyen WJ, et al. Guidelines for radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2008. 35(10):1941–1959.
Article
3. Franzius C, Dietlein M, Biermann M, Fruhwald M, Linden T, Bucsky P, et al. [Procedure guideline for radioiodine therapy and
131Iodine whole-body scintigraphy in paediatric patients with differentiated thyroid cancer]. Nuklearmedizin. 2007. 46(5):224–231.
Article
4. Sisson JC, Freitas J, McDougall IR, Dauer LT, Hurley JR, Brierley JD, et al. Radiation safety in the treatment of patients with thyroid diseases by radioiodine
131I: practice recommendations of the American Thyroid Association. Thyroid. 2011. 21(4):335–346.
Article
5. Barrington SF, Kettle AG, O'Doherty MJ, Wells CP, Somer EJ, Coakley AJ. Radiation dose rates from patients receiving iodine-131 therapy for carcinoma of the thyroid. Eur J Nucl Med. 1996. 23(2):123–130.
Article
6. Culver CM, Dworkin HJ. Radiation safety considerations for post-iodine-131 hyperthyroid therapy. J Nucl Med. 1991. 32(1):169–173.
7. O'Doherty MJ, Kettle AG, Eustance CN, Mountford PJ, Coakley AJ. Radiation dose rates from adult patients receiving 131I therapy for thyrotoxicosis. Nucl Med Commun. 1993. 14(3):160–168.
8. United States Nuclear Regulatory Commission Office of Federal and State Material and Environmental Management Programs 2009 Washington, DC: 20555-0001. NRC Information Notice. 2003. 22:Supplement 2009.
10. Jacobson AP, Plato PA, Toeroek D. Contamination of the home environment by patients treated with Iodine-131: initial results. Am J Public Health. 1978. 68(3):225–230.
Article
11. Harbert JC, Wells N. Radiation exposure to the family of radioactive patients. J Nucl Med. 1974. 15(10):887–888.
12. Berg G, Jacobsson L, Nystrom E, Gleisner KS, Tennvall J. Consequences of inadvertent radioiodine treatment of Graves' disease and thyroid cancer in undiagnosed pregnancy. Can we rely on routine pregnancy testing? Acta Oncol. 2008. 47(1):145–149.
Article
13. Zanzanico PB, Becker DV. Beckers C, Reinwein D, editors. Radiation hazards in children born to mothers exposed 131-iodine. The thyroid and pregnancy. 1991. Stuttgart: Schattauer;189–202.
14. Sawka AM, Lakra DC, Lea J, Alshehri B, Tsang RW, Brierley JD, et al. A systematic review examining the effects of therapeutic radioactive iodine on ovarian function and future pregnancy in female thyroid cancer survivors. Clin Endocrinol (Oxf). 2008. 69(3):479–490.
Article
15. Sawka AM, Lea J, Alshehri B, Straus S, Tsang RW, Brierley JD, et al. A systematic review of the gonadal effects of therapeutic radioactive iodine in male thyroid cancer survivors. Clin Endocrinol (Oxf). 2008. 68(4):610–617.
Article
16. Azizi F, Smyth P. Breastfeeding and maternal and infant iodine nutrition. Clin Endocrinol (Oxf). 2009. 70(5):803–809.
Article
17. Brzozowska M, Roach PJ. Timing and potential role of diagnostic I-123 scintigraphy in assessing radioiodine breast uptake before ablation in postpartum women with thyroid cancer: a case series. Clin Nucl Med. 2006. 31(11):683–687.
Article
18. ICRP Publication 94. nternational Commission on Radiological Protection 2004 Release of patients after therapy with unsealed radionuclides. Ann ICRP. Section 4: Radiation protection after use of therapeutic radiopharmaceuticals, p. 19; Section 10.5: Doses to others during patient travel, Table 10.7, p. 47; Appendix B: Sample instructions for radiation protection after therapeutic administration of radioiodine, p. 71.
19. Dauer LT, Williamson MJ, St Germain J, Strauss HW. Tl-201 stress tests and homeland security. J Nucl Cardiol. 2007. 14(4):582–588.
Article
20. Beasley CW, Moore WH, Wagner LK. Release instructions for hyperthyroid patients treated with I-131. Thyroid. 2011. 21(10):1163–1164. author reply 4-5.
Article